Table 1: Nephron sparing surgery versus radical nephrectomy: clinical, surgical
and pathological parameters.
Parameter |
RN |
NSS |
p-value |
No of patients/No of tumours |
162 |
230/246 |
|
Women/men |
62/100 |
67/169 |
0.039 |
Median age (range) |
65 (26-88) |
67 (23-87) |
0.094 |
BMI |
26.4 (18-44) |
24.8 (19.5-37) |
0.68 |
ASA 3 + 4 |
68 (41.9%) |
78 (33.9%) |
0.77 |
Patients with diabetes |
25 (15.4%) |
31 (13.5%) |
0.56 |
Patients with hypertension |
81 (50%) |
123 (53.5%) |
0.48 |
Preop. creatinine (mg/dl) |
1.0 (0.6-3.4) |
0.94 (0.56-3.5) |
0.811 |
Postop. creatinine (mg/dl) |
1.3 (0.4-4.3) |
1.12 (0.56-4.58) |
0.004 |
Last FU creatinine |
1.2 (0.6-8.8) |
1.08 (0.57-8.51) |
0.002 |
Preop. GFR (ml/min/1.73 m2) |
62 (13-146) |
67.5 (13-109) |
0.115 |
Postop. GFR (ml/min/1.73 m2) |
51 (13-234) |
59.5 (11-113) |
< 0.001 |
Last FU GFR (ml/min/1.73 m2) |
54 (1.73-144) |
65 (6-113) |
< 0.001 |
CKD stage I/II/III/IV/V |
11/90/55/5/1 |
25/140/61/3/1 |
0.648 |
Pathological tumour size; median (range) |
6.2 (0.3-20) |
3 (0.2-18) |
< 0.001 |
Pathology |
|
|
|
Clear-cell |
136 (83.9%) |
156 (63.4%) |
< 0.001 |
Papillary |
13 (8.0%) |
73 (29.7%) |
|
Chromophobe |
6 (3.7%) |
12 (4.9%) |
|
Others |
7 (4.3%) |
5 (2.0%) |
|
Tumor
staging |
|
|
|
pT1 |
79 (48.7%) |
223 (90.6%) |
< 0.001 |
pT1a |
27 (16.6%) |
183 (74.3%) |
|
pT1b |
52 (32.1%) |
40 (16.3%) |
|
pT2 |
28 (17.2%) |
11 (4.4%) |
|
pT2a |
23 (14.1%) |
6 (2.4%) |
|
pT2b |
5 (3.1%) |
5 (2.0%) |
|
pT3 |
50 (30.8%) |
11 (4.4%) |
|
pT3a |
33 (20.3%) |
11 (4.4%) |
|
pT3b |
17 (10.5%) |
- |
|
pT4 |
3 (1.8%) |
1 (0.4%) |
|
N1 (5%) |
4 (2.4%) |
1 (0.4%) |
0.020 |
N2 |
1 (0.6%) |
- |
|
M1 |
16 (9.8%) |
7 (2.8%) |
0.002 |